The present disclosure provides methods for the treatment of migraine by the administration of atogepant or a pharmaceutically acceptable salt thereof.

The present disclosure provides methods for the treatment of migraine by the administration of atogepant or a pharmaceutically acceptable salt thereof.

The present disclosure relates to use of Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide having a chemical structure:

##STR00001##

for the treatment and/or prevention of COVID-19 infection. The present disclosure further relates to a pharmaceutical formulation that is administered in the form of dry powder inhalation (DPI) to the subject. The dry powder inhalation formulation comprises a micronized Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide, a first lactose, a second lactose, and at least one excipient. The pharmaceutical formulation of the present disclosure increases the bioavailability of the NaDCC, has patient compliance, and reduced adverse effects.

The present disclosure relates to use of Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide having a chemical structure:

##STR00001##

for the treatment and/or prevention of COVID-19 infection. The present disclosure further relates to a pharmaceutical formulation that is administered in the form of dry powder inhalation (DPI) to the subject. The dry powder inhalation formulation comprises a micronized Sodium 3,5-dichloro-2,4,6-trioxo-1,3,5-triazinan-1-ide, a first lactose, a second lactose, and at least one excipient. The pharmaceutical formulation of the present disclosure increases the bioavailability of the NaDCC, has patient compliance, and reduced adverse effects.

Pharmaceutical compositions are provided for the treatment, pre-emptive treatment or prevention of acute renal injury.

Pharmaceutical compositions are provided for the treatment, pre-emptive treatment or prevention of acute renal injury.

A dialyzer (15) includes a hollow fiber dialysis column (20), a liquid tubing section (12a), and a flow rate changing section (16a). The hollow fiber dialysis column (20) includes a hollow fiber membrane, a first flow channel that allows a dialysis target to flow internally of the hollow fiber membrane, and a second flow channel that allows an external liquid to flow externally of the hollow fiber membrane. The liquid tubing section (12a) tubes the dialysis target to an inlet (20a) of the first flow channel. The flow rate changing section (16a) is capable of changing a flow rate of the dialysis target at the dialysis target flowing out of an outlet (20b) of the first flow channel.

A dialyzer (15) includes a hollow fiber dialysis column (20), a liquid tubing section (12a), and a flow rate changing section (16a). The hollow fiber dialysis column (20) includes a hollow fiber membrane, a first flow channel that allows a dialysis target to flow internally of the hollow fiber membrane, and a second flow channel that allows an external liquid to flow externally of the hollow fiber membrane. The liquid tubing section (12a) tubes the dialysis target to an inlet (20a) of the first flow channel. The flow rate changing section (16a) is capable of changing a flow rate of the dialysis target at the dialysis target flowing out of an outlet (20b) of the first flow channel.

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an IL-12/IL-23 inhibitor.

An object of the present invention is to develop a novel treatment method for chronic diseases for which conventional treatment methods are either ineffective or for which efficacy is low. The present invention provides a pharmaceutical composition for the treatment and/or prevention of an inflammatory chronic disease that is used in combination with a biological preparation that inhibits leukocyte tissue invasion. The pharmaceutical composition of the present invention contains as an active ingredient thereof siRNA suppressing the expression of CHST15 gene that contains a structure formed by the hybridization of RNA containing the base sequence represented by SEQ ID NO: 1 with RNA complementary thereto.